Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF1808
- Development stage
- Preclinical
- Lead developer
- ImmunoForge
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
PF1808 is an investigational drug candidate developed by ImmunoForge, a biotechnology company specializing in treatments for rare and age-related diseases. The candidate is built upon ImmunoForge's proprietary Elastin-Like Polypeptide (ELP) platform, a half-life extension technology that fuses therapeutic proteins or peptides to ELP biopolymers to improve their pharmacokinetic properties and stability. In current company pipeline disclosures, PF1808 is designated as a "License Out" (L/O) asset. Consequently, specific information regarding its biological target, mechanism of action, and primary therapeutic indications has not been publicly released by the developer.
Beyond the preview
Go deeper on PF1808.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF1808.